# HW071021 Monotherapy in Patients With Advanced Solid Tumors

> **NCT06882135** · PHASE1 · RECRUITING · sponsor: **Wuhan Humanwell Innovative Drug Research and Development Center Limited Company** · enrollment: 76 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HW071021 Tablets

## Key facts

- **NCT ID:** NCT06882135
- **Lead sponsor:** Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-28
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-02-28
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06882135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06882135, "HW071021 Monotherapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06882135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*